NCT04505813 - Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions

Relapsed Refractory Multiple Myeloma

Interventions

BIOLOGICAL

NEXI-002 T Cells

The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.

Trial Locations (6)

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Advent Health Medical Group Blood & Marrow Transplant, Orlando

Karmanos Cancer Institute, Detroit

MD Anderson Cancer Center, Houston

City of Hope Comprehensive Cancer Center, Duarte

Dana-Farber Cancer Institute, Boston